Novartis Ag dropped 1.41% in after-hours trading, following the release of APONTIS PHARMA AG's half-year report 2025, which included a resolution to transfer the shares of minority shareholders. Additionally, Switzerland's GDP growth of 0.1% in Q2 and the EU court ruling against DocMorris' advertising practices for prescription drugs may have contributed to the negative sentiment in the market.
Comments
No comments yet